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ABSTRACT 
 
 
Background: Vaccines are important to public health, but because of the way they are 
manufactured, their mechanism of action, and their indicated population, careful 
monitoring of their adverse events is necessary. Canada has a national surveillance 
system that collects reports on adverse events that may be associated with vaccine 
administration.  Sensitivity is one of the tools used with surveillance systems to study the 
extent and characteristics of reporting of a surveillance system. To date, the sensitivity of 
the Canadian system has not been assessed.  
 
Purpose: To assess the sensitivity of the Canadian Adverse Event Following 
Immunization Surveillance System (CAEFISS). 
 
Methods: Based on specific adverse events following immunization (AEFI) and vaccines 
chosen for the study, a thorough literature search was completed to find the best source 
which identifies expected rates of AEFI. Studies used were assessed based on quality and 
sample size. The expected rates of AEFI, in combination with public health estimates of 
vaccine coverage rates, were used to estimate the expected number of reports. The reports 
provided the actual number of events used to calculate the sensitivity. Sensitivity was 
compared based on year of administration, age group, and type of AEFI.  
 
Results: The overall sensitivity of the CAEFISS varied from 1.0% to 136.6% for various 
AEFI for the years 1997 to 2008. For influenza the sensitivity was found to be 93.6% and 
136.3% for GBS and anaphylaxis respectively. For DTaP, the rates were found to be 
15.0%, 1.0%, and 21.2% for anaphylaxis, HHE, and seizures respectively, and for MMR 
the rates were 16.5%, 52.7%, and 12.7% in relation to anaphylaxis, thrombocytopenia, 
and seizures respectively.   
 
Conclusions: This is the first assessment of the sensitivity of the CAEFISS, and this 
study found that the system has reasonable ability to detect AEFI on a national level. 
CAEFISS had comparable senstivity to other vaccine reporting systems. Many of the 
AEFI had sensitivity values higher than the 5%-10% range traditionally seen in other 
passive surveillance systems related to adverse events. The greatest variation of 
sensitivity was seen between vaccines. Rarity and timing of the AEFI may also impact 
the sensitivity. Variation of sensitivity and the variation found in the sensitivity analysis 
lend to the further development and implementations of case definitions for rarer adverse 
events, especially anaphylaxis. Further research of other factors that impact reporting is 
necessary.  
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CHAPTER 1.  INTRODUCTION 
 
 
1.1 Overview 
 
Vaccines are vital to public health, but because of their method of manufacturing, 
mechanism of action, and indicated population careful monitoring of their safety is 
important. Canada has a national surveillance system which collects reports on adverse 
events temporally associated with vaccine administration. An assessment of the 
sensitivity of the system has not been conducted to date. Such an assessment would allow 
for a better understanding of the system, identify areas for improvement, and reassure the 
public of the merit of such reporting systems. This thesis assesses the overall and annual 
sensitivity of the system for specific Adverse Event Following Immunization (AEFI). 
 
 
1.2 Background 
 
Vaccines are unique medical interventions. They are used for primary prevention of 
disease and are administered to healthy (non-diseased) individuals (Ellenberg & Braun 
2002). This is in contrast to most medical interventions which correct or treat a condition 
of illness. Vaccines are used worldwide, such that every person is recommended to 
receive multiple immunizations over his lifetime. The success of vaccines in reducing 
morbidity and mortality, globally, cannot be overstated. Their effects on overall life 
expectancy have far surpassed those of other medical interventions, especially within the 
pediatric population. Vaccines are biologic products with complex mechanisms of action 
and manufacturing processes (Grabenstein & Grabenstein 1997; Jacobson 2003; Martin 
,Nelson, Hershey, & Engler 2003). Thus, although vaccines are generally safe, like any 
medical intervention, vaccines do present risk (Bonhoeffer & Heininger 2007).  
 
Public perception of vaccines is important. For vaccine effectiveness, herd immunity, 
defined as immunity in a large proportion of a population to ensure the continued 
suppression of disease outbreaks, must be maintained to. Therefore, any perception of 
vaccine risk or ineffectiveness may profoundly affect vaccine uptake, effectiveness, and 
public health. In some instances, vaccine use has been so effective that it may appear to 
the public that the disease has disappeared. This perception of disease eradication by 
vaccines has begun to undermine the value of immunization to the public (Fowler et al. 
2008; Kimmel, Burns, & Zimmerman 2003; O'Hagan & Rappuoli 2004).  
 
Vaccines are designed to induce an immune response, which is the basis for both harm 
and protection.  Rare but serious adverse events can occur due to vaccines, but even large 
clinical studies that serve as the basis for approval may be underpowered to detect these 
events. Vaccine safety can be greatly affected by storage requirements and differences 
between lots, which require unique lot-by-lot monitoring (Letourneau, Wells, Walop, & 
Duclos 2008; Mansoor 1999).  Therefore, because of the importance of vaccines to public 
health, unique considerations, and challenges in identifying rare adverse events, post-
marketing surveillance for vaccines is essential for public health and safety.  
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Surveillance systems are one of the primary methods for post-marketing monitoring. 
Current AEFI surveillance systems rely on spontaneous reporting of AEFI, and therefore, 
these systems are not intended for the detection of new AEFI.  Instead, passive 
surveillance systems focus on ongoing safety monitoring of the products. These systems 
generate associations between vaccines and adverse events and they cannot prove a cause 
and effect relationship. The value and appropriate application of spontaneous vaccine 
surveillance systems was exhibited with the Rotashield rotavirus vaccine. A surveillance 
system generated concern that Rotashield rotavirus vaccine increased the occurrence of 
intussusceptions. However, this increased risk was not confirmed until post-marketing 
studies were completed (Niu, Erwin, & Braun 2001; Verstraeten et al. 2001; Zanardi, 
Haber, Mootrey, Niu, & Wharton 2001). This approach is in contrast to other public 
health surveillance systems in which active surveillance is conducted in order to assess of 
the rate of occurrence of specific events (i.e. active surveillance (German 2000)).  
 
Surveillance systems have been an integral tool in assuring vaccine safety, since they are 
designed for ongoing collection, analysis, interpretation, and application of data 
("Immunization information systems progress--United States, 2006," 2008).  These 
systems are capable of analyzing long-term trends and changes, but more importantly, are 
used for immediate action if a signal of increased risk becomes apparent.  Although many 
specific attributes of reporting and public health systems have been evaluated, the 
analysis of sensitivity of an AEFI reporting system holds importance (German et al. 
2001).  To establish quality and dependability, the United States Center for Disease 
Control (CDC) published guidelines for the analysis of public health reporting and 
surveillance systems (German et al. 2001). While these guidelines focus on many aspects 
of public health surveillance systems, recommendations for sensitivity analysis are 
relevant to AEFI reporting. 
 
CAEFISS was created to serve as a national monitoring system for reporting AEFIs. The 
current system allows healthcare professionals, consumers, public health workers, and 
vaccine manufacturers to report AEFIs. The CAEFISS objectives are to ensure continued 
safety of vaccines in Canada, monitor AEFI, identify any unusual rates of AEFI within 
specific vaccines and lots, provide timely information to healthcare providers to help 
weigh the risks and  benefits of immunizations, and to identify specific areas that may 
require further epidemiological evaluations. Currently, the majority of CAEFISS is 
spontaneously reported, but a portion of the system is active through the IMPACT 
program. IMPACT is an active surveillance program which includes 12 Canadian 
hospitals accounting for 90% of all tertiary care pediatric beds in Canada. The 
implementation of the IMPACT program has increased awareness of vaccine safety and 
created a targeted goal of improving vaccine safety for the pediatric population (Scheifele 
& Halperin 2003).  
 
The sensitivity of a surveillance system is calculated as the proportion of events in a 
specific population that are actually reported. In lay terms, sensitivity measures the 
proportion of actual events that are reported to the system.  Sensitivity is important to 
maintain the ability to detect changes over time, which is directly related to the 
proportion of reports. The need to assess sensitivity has special importance for systems 
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that rely on spontaneous reporting. Although higher sensitivity is indicative of a better 
system in applications such as diagnostic tests, the CDC guidelines state that sensitivity 
in public health surveillance systems is not directly related to the reporting systems 
effectiveness. In public health reporting systems, detecting even with low sensitivity is 
especially important. Low sensitivity may indicate a need for improvement and an 
inability to respond quickly to reports.  
 
Sensitivity of systems can be improved through changes that allow greater simplicity and 
timeliness of reporting. The analysis of the sensitivity of the system can be used to 
evaluate the extent of reporting to the system.  Consistent analysis of any surveillance 
system should be conducted to assure its integrity and assist improvement.  
 
The CDC has performed an analysis of sensitivity of the US Vaccine Adverse Event 
Reporting System (VAERS) and continues to do so annually (Rosenthal & Chen 1995; 
Zhou et al. 2003). Research of the US Vaccine Surveillance System demonstrated that 
sensitivity varies by AEFI (Goodman & Nordin 2006). There are no published data on 
the sensitivity of the CAEFISS. Sensitivity indicates how well a surveillance system 
functions. By assessing how various factors affect the sensitivity a better understanding 
will be gained of how certain issues may cause changes in the extent of reporting. These 
data will be useful to determine ways to improve the Canadian system.  
 
 
1.3 Purpose of Study 
 
The purpose of this study was to assess the sensitivity of the CAEFISS between 1997 and 
2008. The study looked at selected vaccines and AEFI based on variation in the indicated 
population, severity, and incidence to allow for maximum variation and insight into the 
characteristics of the Canadian system.  
 
 
1.4 Specific Aims and Hypotheses 
 
 
1.4.1 Specific Aims 
 
There were three specific aims. First, this thesis ascertained the sensitivity of the 
CAEFISS.  Second, this study assessed the variability of the sensitivity for selected AEFI 
over time. This study used the combination of the overall sensitivity and the stability of 
the sensitivity over time to better understand the characteristics of the system. Third, this 
study compared AEFI in relation to their rarity, timing of occurrence, and patient age as 
possible factors affecting sensitivity.  
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1.4.2 Hypotheses 
 
Based on past studies of sensitivity related to AEFI surveillance systems, existing 
structures of the Canadian system, and changes of vaccine knowledge over time, the 
following hypotheses were made:  
 
 Rarer AEFI will have higher sensitivity. This hypothesis parallels the works 
in assessments of other vaccine adverse event systems and general thoughts 
on reporting systems found in the literature (Rosenthal & Chen 1995). The 
literature clearly indicates that when an AE is seen more often or known to 
have a strong correlation, there is a decreased likelihood of reporting (Lopez-
Gonzalez et al. 2009).  
 AEFI that have a rapid onset will have a higher sensitivity. The sensitivity to 
events that have a rapid onset will be higher because the time to onset is 
smaller thus the reporters conclude a temporal association of the event.   
 There will be greater sensitivity for AEFI following vaccines given to 
children as opposed to those given to adults. Pediatric vaccinations will have 
a higher sensitivity than the adult vaccinations. This hypothesis is based on 
two factors: first there is greater awareness and experience with vaccines 
among healthcare providers caring for children, and second, the active 
surveillance system for adverse events among hospitalized children is 
conducted by IMPACT (Scheifele & Halperin 2003).  
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CHAPTER 2. LITERATURE REVIEW 
 
 
2.1 Methodology of Search 
 
A literature review was conducted to locate previous studies addressing the sensitivity of 
AEFI surveillance systems. A thorough literature review was conducted using both 
MEDLINE and EMBASE databases from January 01, 1980 through the date of May 31, 
2009. A search using the keywords “vaccine”, “surveillance systems”, “sensitivity”, 
“Canada”, and “adverse events” was conducted and articles pulled for relevance.  Also 
websites of key organizations (CDC, PHAC, and the World Health Organization (WHO)) 
were searched for relevant material on the topic. Secondary to both searches, all papers 
that were pulled had their references reviewed for possibly relevant articles, and a search 
for related articles was also conducted. In addition, a search for MeSH terms was done to 
check the results of the keyword search. The articles were included if they had any 
relevance related to the assessment of AEFI reporting systems, assessment of reporting 
systems, sensitivity assessment of AEFI  surveillance systems, or assessment of vaccine 
safety.  Inclusion of papers was limited to those written in the English language and 
studies of humans. All abstracts and relevant papers were pulled for further review to 
assess their inclusion and relevance.  
 
 
2.2 Search Results 
 
The initial Keyword search using  “vaccine”, “surveillance systems” , “sensitivity”, 
“Canada” , and “adverse events” yielded 0 hits; thus, a search excluding the term 
“Canada” was conducted. This secondary and broader search yielded 4 hits with only one 
relevant article found: Rosenthal et al. (1995). The search was then expanded utilizing 
“vaccine” or “adverse event” AND “sensitivity” AND “surveillance systems”. After 
duplicates were eliminated, this third search yielded 20 papers with no newly added 
relevant articles. The search was again broadened to include  “vaccine” and “surveillance 
system” and yielded 173 unique papers, of which 7 were somewhat relevant to AEFI 
surveillance systems, 2 looked at sensitivity assessment of the systems, and 1was found 
in the previous search (Rosenthal & Chen 1995). These two papers describing sensitivity 
assessments are discussed in depth in the next sections of this chapter.  Other papers had 
relevant information pertaining to AEFI surveillance systems or vaccine safety in general. 
To ensure that no articles were missed due to the need to broaden searches and the 
obvious lack of publications in this area, all relevant papers had their citations searched in 
attempt to identify relevant articles. No further relevant studies were found in the 
additional related papers and MeSH term search.  
 
The last portion of the systematic search was the search of the websites of major public 
health organizations for information. These official websites, especially those of the CDC 
and WHO, yielded relevant information. For example, the CDC website contained 
general guidelines for the assessment and maintenance of public health reporting systems 
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and, of even greater importance, a discussion of the utilization of sensitivity as an 
important assessment tool.  
 
 
2.3 Assessment of Surveillance Systems 
 
The systematic search only found one study of relevance to the assessment of sensitivity 
of a system and one study comparing sensitivities of AEFI surveillance systems. At this 
time, there are no published studies evaluating the sensitivity rates of CAEFISS. 
Rosenthal et al. (1995) conducted the only major study, which assessed the sensitivity of 
the CDC system in the US between the years of 1985 and 1990 for the United States 
VAERS. VAERS is the United States’ national vaccine surveillance program co-
sponsored by the CDC and the FDA (Varricchio et al. 2004). The system is a 
spontaneous safety surveillance system used to report any AEFI in the United States 
(Iskander, Pool, Zhou, & English-Bullard 2006; Zhou et al. 2003).  
  
Rosenthal et al. (1995) measured sensitivity for a number of selected vaccines and AEFI 
pairs. They looked at Oral Polio Vaccine (OPV) - Vaccine Associated Paralytic Polio 
(VAPP), MMR-seizures, MMR-thrombocytopenia, MMR-rash, and DTP-HHE and DPT-
seizures.  All vaccines and AEFI pairs selected had a proven causal association, as well 
as an estimated frequency of occurrence. The study used evidence from the published 
literature to estimate the expected incidence rates of selected AEFI. The number of 
vaccines doses administered was estimated using: (1) doses purchased with public sector 
funds and (2) numbers of doses distributed by manufacturers less doses returned by 
providers (3) the National Health Interview Survey (NHIS) was used for specific 
childhood vaccinations coverage rate estimates. Using the AEFI rates from the literature, 
in combination with the estimate of the number of doses administered, the expected 
number of AEFI occurring was estimated.  The number of AEFI reported is divided by 
the expected number of AEFI to calculate the sensitivity for each specific AEFI. The 
sensitivity was calculated for overall estimates and separately for only publically 
administered vaccines.  In order for reports to be included as an AEFI they had to meet 
specific criteria based on timing and age group of the event in reference to the 
administration.  The study found a large range in reporting sensitivity related to the rarity 
and severity of AEFI. Specifically the sensitivities for reporting poliomyelitis after 
administration of OPV was 72% whereas it was less than 1% for rash and 
thrombocytopenia after administration of the MMR vaccine.  The authors’ discussed the 
issues related to the underreporting of new and rare AEFI, inadequate information 
reported, and effects of publicity on reporting rates. The authors went to state that 
sensitivity may also be associated with clinical severity, temporal proximity to 
vaccination, and healthcare workers’ obligations to report particular AEFI. The authors 
also discussed the need for case-definition that would allow reports to be more efficiently 
decoded and assessed.   Currently the CDC completes the same style analysis annually 
but does not publish their results.  
 
McNeil et al. (2007) compared the sensitivity of the VAERS system to that of the 
independently operated US military AEFI Surveillance system.  The outcome was used to 
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assess the agreement between two systems utilizing a sensitivity value, in which the 
number of VAERS reports was considered the denominator compared to the number of 
matching reports in the military system.  The analysis was completed with all anthrax 
related AEFI reports as well as all vaccine reports. The sensitivity of the anthrax only was 
found to be 74% and 73% for all vaccines. In other words, the military AEFI surveillance 
system picked up on 74% and 73% of reports that were also reported to the VAERS. 
Although the systems are interconnected, the study showed the dynamic nature of many 
of these AEFI surveillance systems. Moreover, it serves as another example of 
differences in sensitivity rates based on AEFI, although they referred to the exact same 
events between systems.  
 
 
2.4 Assessing Sensitivity of Surveillance System 
 
The CDC published a guideline for the analysis of public health reporting system and 
surveillance systems (German et al. 2001). This guideline applies to all surveillance 
systems; it discusses many important characteristics that need to be assessed in any 
system to ensure its quality and dependability of reporting. One of the major factors listed 
as necessary for assessment of any system is that of sensitivity. The need to assess 
sensitivity is highly emphasized in the guidelines, especially in systems in which passive 
reporting is utilized. Low sensitivity may indicate a need for improvement and a lack of 
ability to respond on time to the reports. The guidelines do add an important note that 
sensitivity is not directly proportional to how well the system is working. Higher 
sensitivity of one system may not be equivalent to concluding that one system is 
performing better than another system. 
 
Even more important than a higher sensitivity is having sensitivity that is high enough to 
detect changes coupled with stability of the value over time.  Sensitivity of systems can 
be improved through changes that will allow for greater simplicity and timeliness of 
reporting. The guidelines describe sensitivity as the number of reports collected, divided 
by the number of reports expected in a specific population under surveillance. The report 
further emphasizes the need for comparison to literature for expected rates. This parallels 
the way that sensitivity was analyzed in the Rosenthal et al. (1995) study and this study. 
 
The guidelines discuses how improvement in sensitivity over time can indicate increased 
awareness, improvements in technology, or can show artifacts necessary for assessment.  
The guidelines continually state the importance of continuous analysis of any system in 
place in order to assure its integrity and continuous improvement (German et al. 2001).  
 
 
2.5 Assessment of Drug Adverse Event Reporting Systems 
 
A separate search was conducted for relevant literature related to the assessment of 
spontaneous AE surveillance systems related to drugs. Literature in this area was much 
broader than that found related to vaccine topics. There was a separate MeSH term 
specific for adverse drug reaction surveillance systems but when combined with 
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measures of sensitivity there was still a small number of published articles. A further 
keyword search and related articles search was also conducted to ensure the search was 
thorough and extensive in nature. The majority of the literature utilizing sensitivity was 
found to be related to the assessment of hospital or smaller specific systems rather than 
national or regional systems. A great deal of the recent published literature is related to 
the creation of signal detection models and applications of various techniques and 
systems of detection (Handler et al. 2008; Jhung et al. 2007; Koh & Li 2005; Majdzadeh 
& Pourmalek 2008; Nebeker et al. 2007; Visweswaran, Hanbury, Saul, & Cooper 2003). 
To further ensure the results from the search were valid, the FDA information service 
was contacted and the question submitted and there was no internal data or published 
reports made available related to sensitivity or other sorts of published assessments.  
 
In the studies of smaller systems, the sensitivity is calculated by examining the ratio of 
the actual number of reports to the true number of events using a gold standard 
(presumably active) method of surveillance (Betancourt, Hakre, Polyak, & Pavlin 2007). 
For example, in a paper published by Hwang et al. (2008) looking at a computer-based 
adverse event monitoring system, the number of reports picked up by the system was the 
actual number (numerator) and the number of reports picked up by a pharmacist 
assessment of the records is noted as the expected (denominator). These two values were 
then calculated to estimate the sensitivity of their system (Hwang, Lee, Koo, & Kim 
2008). The sensitivity of this computer detection system was found to be 79%. 
 
Few studies had a national level assessment of sensitivity. Studies looking at regional and 
national reporting in Europe have concluded that the reporting rates would remain around 
5% for all adverse drug reactions nationally (Begaud, Martin, Haramburu, & Moore 
2002). In a study published by McAdams et al. in 2007, the extent of reporting to the 
FDA adverse event reporting system was estimated for rhabdomyolsis related to statin 
use (McAdams, Staffa, & Dal Pan 2008). Their study utilized cohort incidence rate 
estimates, national distribution estimates of statins, and average day supplies to estimate 
the number of US statin-associated cases of hospitalized rhabdomyolsis. This ‘expected’ 
value was then compared to the observed number of reported cases. This value was 
referred to as the estimated extent of reporting and was reported separately for every type 
of statin. This value is calculated similarly to sensitivity but was not referred to as such. 
The study found that the extent of reporting varied from 5% to 31.2% for specific statins. 
The authors were able to document surveillance system responsiveness to targeted efforts 
to improve reporting sensitivity. Specifically a mass campaign using “Dear Healthcare 
Provider” letters led to increased reporting for cerivastatin from 14.8% to 35.0%. 
 
 
2.6 Summary 
 
Sensitivity has been cited as a useful mechanism of assessing reporting to surveillance 
systems in much of the literature as well as the CDC guidelines. Despite this noted 
importance of the assessment of sensitivity, the literature shows a gap in assessments of 
both drug and AEFI national surveillance systems. Only one study evaluating a national 
AEFI surveillance system has been published, and was published in 1995. More 
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specifically, there is no published work assessing the sensitivity of CAEFISS. Thus this 
study is unique in that it provides information on the sensitivity of the CAEFISS. The 
analysis of sensitivity of these systems is helpful in filling an identified gap in the 
literature and gaining a better understanding of the characteristics of the system in hopes 
for future improvements. 
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CHAPTER 3. METHODS 
 
 
3.1 Overview of Methods  
 
The methodology used to complete this study can be broken into various steps (Figure 
3.1). Each is essential for creating the model used to estimate the values needed to 
calculate and assess the sensitivity. The model was used to assess which characteristics of 
the system affect the extent of reporting. The model used to calculate the expected 
number of AEFI comprises: the published rates of selected AEFI based on proven causal 
associations, the estimated number of vaccines administered and the calculated expected 
number of events. Sensitivity was then calculated based on the ratio of observed to 
expected AEFI reports.   
 
Each of these values can be broken into separate steps and used in the final model and 
calculations of the sensitivity.  The overall sensitivity was calculated for the total study 
time period, from 1997 through 2008 as well as yearly values within that time range. All 
of the variables used in the model and calculation were analyzed utilizing Excel.  
 
A descriptive analysis looking at the number of reports in total meeting the criteria as 
well as by professional affiliation, AEFI type, age groups, and year was conducted and 
reported. This descriptive analysis gave us an understanding of the variation in the 
quantity of reports received. 
 
Overall, the selection of the vaccines and their associated AEFI was conducted in a 
manner that allowed for the greatest variation in age group indication, timing of AEFI, 
and seriousness related to the AEFI selected. Selection of vaccines and AEFI were based 
upon the following criteria (Table 3.1):   
 
1)  A known correlation between the vaccine and the AEFI.  
 
All of the selected AEFI have been accepted with certainty in the literature to be 
associated with the specific vaccine. Evidence for correlation was drawn from 
CDC MMWR Reports, Institute of Medicine (IOM) reports, and past sensitivity 
studies (Fiore et al. 2009; Rosenthal & Chen 1995; Stratton et al. 2001).  
 
2)  Vaccines routinely administered and recommended to large proportions of the 
Canadian population. 
  
Newer vaccines (within the last 10 years) and travel vaccines were not included in 
this study. It is important to note that although newer vaccines were not included 
some vaccine types may have had newer product lines or changes in formulation 
during the indicated time period of this study.  These were included. 
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Step 1 Based on the AEFI and vaccines chosen, a thorough literature search was conducted to find the expected rates of AEFI. 
Step 2 PHAC and WHO statistics and survey estimates were used to estimate the coverage rates of all vaccines in question over the years of the study. 
Step 3 Census Data was used to estimate population sizes. 
Step 4 Based on the values developed in Steps 1 -3 a model was created to calculate the expected number of AEFI. 
Step 5 Sensitivity was calculated per year and overall. Sensitivity was trended over years in question. 
Step 6 One-way and two-way sensitivity analysis of the sensitivity value was conducted. 
 
 
Figure 3.1 Step-wise Approach to Analysis 
 
Notes: These steps are discussed in full detail in their respective sections in this chapter.  
PHAC is used to indicate current as well as former activities when the agency was still 
part of Health Canada.  AEFI=Adverse Event Following Immunization; PHAC=Public 
Health Agency of Canada; WHO=World Health Organization. 
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Table 3.1 Vaccines and AEFI to be Analyzed by Temporal Association of AEFI 
 
 Timing of AEFI 
Vaccine Minutes to Hours Days Weeks 
Influenza Anaphylaxis  GBS 
DtaP Anaphylaxis HHE Seizures  
MMR Anaphylaxis  Thrombocytopenia Seizures 
 
DTaP=Diphtheria Tetanus and Acellular Pertussis Vaccine; MMR=Measles, Mumps, and 
Rubella Vaccine; HHE=Hypotonic-Hyporesponsive Episode; GBS=Guillan-Barre 
Syndrome 
 
 
3)  Analysis of vaccine and AEFI in previous evaluations of surveillance systems 
(some but not all selected met this criterion) (Rosenthal & Chen 1995). 
 
These AEFI include seizures, HHE, and thrombocytopenia. Anaphylaxis and GBS 
were not analyzed in the previous related study.  
 
4)  Vaccines used in a variety of age groups. 
 
MMR and DTaP are routinely administered to infants and children versus 
influenza vaccination which was only analyzed for adults. 
 
5)  Variation in timing of AEFI. 
 
Events occurring within hours of vaccine administration include anaphylaxis.  
Those occurring within days are HHE, severe site reactions, and seizures 
associated with DTaP those within weeks are GBS associated with influenza 
vaccination, thrombocytopenia and seizures associated with MMR vaccination.  
 
 
3.2 Estimating Expected Rates of AEFI 
 
In order to derive the expected rates for the AEFI, a systematic literature review was 
performed using MEDLINE. A search was completed for each vaccine, as well as the 
AEFI of interest (Table 3.1).  A keyword search using the name of the vaccine and the 
AEFI was conducted. Only English language and human studies were included. Studies 
retrieved included guidelines, clinical trials, and large epidemiological studies as well as 
accepted tertiary resources related to AEFI. Acceptable tertiary resources included 
textbooks and organizational guidelines. All publications used had their citations 
searched for further relevant literature. When there was clear discordance in published 
rates efforts were made to select the estimate from the most methodologically sound 
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study based on design, power and when it was performed. For each vaccine and AEFI, 
these published and selected expected rate values were used in the model as the expected 
incidence of the AEFI.  
 
 
3.3 Estimating Expected Number of AEFI 
 
The next step was to determine the estimated doses of vaccines administered within a 
time period. This number can only be estimated because Canada does not currently have 
a national vaccine registry.  An estimated value was derived from the following pieces of 
information: the number of individuals within an age group indicated to receive the 
vaccine and the coverage rates for that specific vaccine.  
 
 
3.3.1 Population Statistics 
 
The first component used in the estimates is the population eligible for immunization for 
a specific vaccine. All population statistics were drawn from Statistics Canada 
(CANSIM) utilizing the E-STAT online interface (CANSIM : summary directory 2001). 
Population census data was drawn for every year between 1997-2008 by year and age 
group. Each vaccine had its indicated population calculated per year. The indicated 
population can vary per year as the recommendations made by the PHAC change over the 
years (Canadian immunization guide : user survey : final report 2005). For each year 
research was done by looking at releases of the Canadian Communicable Disease Report 
(CCDR) to see if any variations occurred in the age indications of specific vaccines. For 
the purposes of this study, the annual population for influenza vaccine was all individuals 
12 years of age and older. For DTaP, the population comprised children in their first few 
years of life for the 5 injection series.  This is the same population as evaluated for the 
two injection series for MMR.  
 
 
3.3.2 Coverage Rates 
 
The coverage rate for a vaccine is the proportion of the indicated population who actually 
received the vaccine in the specified time period. This information can be drawn from 
published coverage statistics and health surveys conducted by the WHO and PHAC. The 
WHO/UNICEF review of national immunization coverage is up-dated yearly and reviews 
many countries immunization rates for various vaccines. For Canada the reports used 
independent surveys conducted by both UNICEF and the WHO, as well as national 
surveys conducted by organizations within Canada. The report contains coverage rates 
for the first DTaP and third DTaP vaccinations from 1987 through to 2008.  
 
For the influenza vaccination coverage rate, the Canadian Community Health Survey 
(CCHS) was utilized. CCHS is a national health survey conducted every 2-3 years to 
collect information related to health status, health care utilization, and health 
determinants of the Canadian population (Beland 2002). Although the survey is designed 
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to cover an array of topics related to healthcare, a portion of the survey is used to estimate 
the influenza vaccination rates for those aged 12 years and above. For intervening years 
when data were not collected an extrapolated trend value was used to fill the gaps. For 
example, for 1997, the rate found in the survey was 15% and in 2000 the survey found a 
rate of 27%. That suggests there was an increase of 12% over a 3 year period. This value 
was then averaged over the 3 years allowing for an annual increase of 4% in the rate, so 
that the rate was 19% and 23% for 1998 and 1999 respectively.  
 
Lastly, the National Immunization Coverage Survey, which is conducted biannually by 
PHAC, was used to attain coverage rates. This survey is mailed out nationally to assess 
immunization coverage rates for 2 and 7 year olds. The survey contains information for 
four injections of DTaP and the first injection of MMR in those 2 years and younger. It 
also contains coverage rates of 5 injections of DTaP and 2 injections with MMR for 7 
year olds. The survey also contains data regarding the median timing of administration 
within a window of time. All three data sources were used to determine the best estimate 
per year of the coverage within the specific indicated population. The resources used for 
these estimates come from nationally and internationally, credible and non-biased 
resources. The resources have been used in many published works.  
 
 
3.3.3 Estimating Doses Administered and Expected Number of Events 
 
Using the per year specific estimates of the indicated population and the year-specific 
estimated coverage rates, the two values were multiplied to calculate the estimated 
number of doses administered for a year (Equation 3.1). This value was then calculated 
for each year between 1997 and 2008. The total number of doses administered in that 
time period was also totaled in order to calculate the total number of doses given in the 
time period of interest. This value was then used to estimate the total number of events 
expected (Equation 3.2). 
 
Equation 3.1 Calculation of Estimated Number of Doses Administered: 
 
Estimated Number of Doses Administered (Nev) / Year = Coverage Rate in specific Year 
(Cr) * Population Indicated (Ni) 
 
Equation 3.2 Calculation of Estimated Number of Events: 
 
Estimated Number of Events/Year (Ned) = Estimated Number of Doses Administered (Nd) 
* Event Rate (Ni) 
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3.4 Number of Events and Calculating Sensitivity 
 
The number of reports was drawn from the CAFISS database.  This database has a record 
of each AEFI reported to the government from consumers, public health, and healthcare 
providers. All events reported between 1997-2008 were used. The data had no patient 
identifying information. Specific data obtained for this study was the year vaccine was 
administered, type of vaccine(s) administered, type of AEFI, age group, and reporter 
professional affiliation. 
 
The sensitivity value for each AEFI specific for each vaccine was calculated by dividing 
the number of actual reports by the expected number of reports (Equation 3.3). This 
value was calculated for each year and overall for the time period in question. The 
sensitivity trend for each AEFI was compared over time to assess for stability over time. 
Any reports related to the whole-cell pertussis vaccines and all data from 1997 were 
excluded to ensure that this transition year did not affect the DTaP sensitivity.  
 
Equation 3.3 Sensitivity Calculation: 
 
Sensitivity (S) = Number of Actual reports (Na)/ Number of Expected Reports (Ne) *100% 
 
 
3.5 Sensitivity Analysis 
 
All values used and assumptions of any model are subject to variation and the possibility 
of error. A sensitivity analysis was used to assess the impact of variations in the 
assumptions used in the calculations. The first one-way sensitivity was conducted by 
varying the expected rates used in the model by +/- 5%. A one-way sensitivity analysis 
was also conducted for the coverage rates assuming a +/- 5% variance. The two-way 
analysis was a combination of the one-way analyses in which the variation of the 
coverage rates and the expected rates of AEFI were investigated simultaneously.  This 
resulted in 4 two-way analyses. 
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CHAPTER 4. RESULTS 
 
 
4.1 Expected Rates of AEFI 
 
Utilizing a through literature review as described in the previous chapter, the expected 
rates of AEFI and the vaccines of interest were found (Table 4.1). All rates of AEFI rates 
are reported as the number of cases per number of doses administered. Some AEFI such 
as GBS with influenza, HHE with DTaP, seizures with MMR and DTaP, and 
thrombocytopenia with DTaP have known rates that are well documented in the literature 
and there is a general consensus behind their rates of occurrence. Anaphylaxis with 
influenza and MMR had rates that greatly varied from each other.  Rates were selected 
from the largest, best-designed studies. 
 
 
4.1.1 Influenza 
 
Influenza vaccination adverse event rates were inconsistent. Anaphylaxis was analyzed 
for influenza as well as the other two vaccines of interest. Two relevant articles for the 
rate of anaphylaxis with influenza vaccine were found. One study was a review article 
(Zent 2002) discussing the possible causes for anaphylaxis and the rate of 0.65 cases per 
million doses was concluded. The articles go on to state that in general the rate would be 
around 1 case per million doses administered. The data used was drawn from a VAERS 
system. The second study was that of Bohlke et al. (2004) which utilized data from 
HMOs for the pediatric population. They did not report any anaphylaxis cases related to 
influenza with 197,964 doses administered. They estimated the general risk with any 
anaphylaxis within the pediatric population was around 0.65 cases per million doses 
administered. This rate was derived from a general risk of anaphylaxis with any 
vaccination for the pediatric population. The rate of 1 case per million was selected due 
to its general consensus in textbooks and review articles for any vaccination (Bohlke et 
al. 2003; Grabenstein & Grabenstein 1997; Nokleby 2006).  For GBS all studies were in 
agreement that there is 1 excess case per million doses (Babl, Lewena, & Brown 2006; 
Bonhoeffer, Heininger et al. 2004; Juurlink et al. 2006; Lasky et al. 1998; Souayah, 
Nasar, Suri, & Qureshi 2007).  
 
 
4.1.2 DTaP 
 
For DTaP, three separate AEFI were assessed. For anaphylaxis the rate with DTaP 
vaccination was found to be 8.6 cases per million doses (Bohlke et al. 2003). For HHE 
the accepted rate of occurrence was reported as 140 cases per 140,000 with the acellular 
pertussis containing vaccine (Babl et al. 2006; Bonhoeffer et al. 2004; Braun et al. 1998; 
DuVernoy & Braun 2000). A rate of 0.22 cases of seizure per 1000 doses with DTaP 
vaccination was selected (Chen, Mootrey, & DeStefano 2000; Le Saux et al. 2003).  
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Table 4.1 Expected Rates of AEFI Based on Literature 
Vaccine AE 
Rates per 
Doses 
Administered 
Type of Study/Reason 
Influenza 
 
Anaphylaxis 1 case per 
million 
Review article/consensus 
 GBS 1 case per 
million 
Consensus 
DTaP Anaphylaxis 8.6 cases per 
million 
Review/Epidemiological 
 HHE 140 cases per 
100,000 
Consensus- Epidemiological 
 Seizures 0.22 cases per 
1000 
Consensus-RCT 
MMR Anaphylaxis 14.4 per 
million 
Epidemiological 
 Thrombocytopenia 
(ITP) 
1 case in 
30,000-40,000 
Consensus- Epidemiological 
 Seizures 1case per 1000 Consensus-RCT 
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4.1.3 MMR  
 
Three AEFI for MMR were assessed. For anaphylaxis, the literature was found to have 
varying rates. The rate used was 14.4 cases per million doses administered. The rate 
selected was from a large epidemiological study mentioned above that utilized large 
HMO data sets to assess the incidence of anaphylaxis (Bohlke et al. 2003). This large 
dataset has been utilized in prior studies for the vaccine safety datalink and contains 
approximately 6 million persons worth of data (Chen, DeStefano et al. 2000). Other 
reported rates, that were not selected, were calculated utilizing surveillance systems. Due 
to their intrinsic limitation, these systems were not well suited to capture the incidence 
within a population (Babl, Lewena, & Brown 2006). One study utilized measure of IgE 
antibody to attempt to quantify the rate of anaphylaxis (Pool et al. 2002). The study found 
a rate closer to the concluded rate from the Bohkle et al. (2003) study which was 
substantially higher that the rates drawn from surveillance systems.  
 
The other two AEFI were thrombocytopenia and seizures both of which have consensus 
rates that are drawn from both RCTs and epidemiological studies (Babl et al. 2006; 
Grabenstein & Grabenstein 1997; Miller et al. 2001; Stowe, Kafatos, Andrews, & Miller 
2008; Stratton, Howe, Johnston Jr, & Majewski 1994). Thrombocytopenia had a rate of 1 
case per 30,000 doses administered and seizures had a rate of 1 case per 1000 doses 
administered.  
 
 
4.2 Estimated Number of Vaccines Administered 
 
 
4.2.1 Coverage Rates 
 
The estimated number of vaccine doses administered was calculated from the coverage 
rates (Table 4.2) and the size of the indicated population. It was evident that in both the 
DTaP and MMR series coverage rates decreased further into the series.  DTaP coverage 
dropped from an estimate of 97-98% for the first dose to 85-94% for the third and 68% 
for the 5th dose in the series. MMR had the same trend of a 96% coverage rate for the first 
injection in the series throughout most years with a drop to 74% for the second injection.  
Influenza vaccination over the years had a general upwards trend in the coverage rate 
with only 15% in 1997 and reaching 34% in 2005-2008 (Figure 4.1).  
 
 
4.2.2 Targeted Population and Estimated Doses Administered 
 
The second value important to the computation of the number of doses administered is 
that of the size of the indicated population (Table 4.3). There were a total of 42,091,244 
doses of DTaP, 12,708,045 doses of MMR, and 90,779,438 doses of influenza vaccines 
estimated to have been administered between the years of 1997-2008. The table below 
depicts the numbers attributed to each year as well as the number of individuals who 
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Table 4.2 Coverage Rates by Source and Year  
Vaccine Data Source 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 
Influenza 
Canadian 
Community 
Health Survey 
15% 19%* 23%* 27% 27%* 28%* 28% 31%* 34% 34%* 34%* 34%*
DTaP WHO Estimate - DTP 1 Dose 98% 98% 97% 97% 97% 97% 97% 97% 97% 97% 97% 97% 
 CHS Estimates – DTP 2 Dose 92% 94% 96% 94% 94% 95% 94% 96% 96% 96% 96% 96% 
 WHO Estimate - DTP 3 Dose 86% 90% 94% 91% 91% 93% 91% 94% 94% 94% 94% 94% 
 
CHS  7 year 
olds Injection 4 
(2002) 
75% 75% 75% 75% 75% 75% 75% 75% 75% 75% 75% 75% 
 
CHS -7 year 
olds Injection 5 
(2002) 
68% 68% 68% 68% 68% 68% 68% 68% 68% 68% 68% 68% 
MMR 
CHS  7 year 
olds Injection 1 
(2002) 
96% 96% 96% 96% 96% 96% 96% 96% 96% 96% 96% 96% 
 
CHS -7 year 
olds Injection 2 
(2002) 
74% 74% 74% 74% 74% 74% 74% 74% 74% 74% 74% 74% 
 
Notes: * These values for influenza are extrapolations and no value was available for this year. All values found in multiple 
sources did not vary by more than 2% in coverage rate. Rates of influenza are based on the total population aged 12 and older. 
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Figure 4.1 Estimated Canadian National Immunization Coverage Rates for Influenza, DTaP, and MMR from 1997-2008
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Table 4.3 Indicated Population and Total Doses per Year from 1997-2008 
 
 
Influenza  
 
DTaP 
 
MMR 
 
Year 
 Indicated 
Population 
Doses 
Administered 
 
Indicated Population 
 Doses 
Administered  
 
Indicated Population  
 Doses 
Administered 
 Seasonal 
Injection Total 
 Injections 
 1-3 
4th 
Injection 
5th 
Injection Total 
 
Total 
 1st 
Injection 2
nd Injection Total 
 
Total 
1997  25,146,615 3,771,992  1,069,785 381,771 408,589 1,860,145  1,548,371  381,771 387,807 769,578  653,478 
1998  25,427,796 4,831,281  1,034,736 360,180 402,518 1,797,434  1,516,499  360,180 384,062 744,242  629,979 
1999  25,711,987 5,913,757  1,015,290 349,055 396,632 1,760,977  1,501,103  360,180 363,195 723,375  603,857 
2000  26,022,202 7,025,995  1,016,418 343,564 393,530 1,753,512  1,480,706  343,564 353,210 696,774  591,197 
2001  26,391,775 7,125,779  995,583 345,751 386,870 1,728,204  1,458,233  343,564 349,540 693,104  590,581 
2002  26,785,043 7,365,887  983,997 336,122 376,585 1,696,704  1,442,967  343,564 349,264 692,828  581,132 
2003  27,141,304 7,599,565  990,678 332,651 364,935 1,688,264  1,428,881  343,564 339,382 682,946  570,488 
2004  27,498,648 8,524,581  1,014,090 335,567 358,767 1,708,424  1,464,093  335,567 336,889 672,456  571,442 
2005  27,847,352 9,468,100  1,017,642 344,046 354,012 1,715,700  1,470,611  344,046 340,309 684,355  582,113 
2006  28,205,075 9,589,726  1,050,273 345,449 351,268 1,746,990  1,500,959  345,449 348,535 693,984  589,557 
2007  28,576,333 9,715,953  1,069,674 354,142 349,395 1,773,211  1,524,734  354,142 349,049 703,191  598,273 
2008  28,961,242 9,846,822  1,090,365 360,775 352,902 1,804,042  1,551,853  360,775 358,244 719,019  611,445 
     
Total  323,715,372 90,779,438  12,348,531 4,189,073 4,496,003 21,033,607  17,889,010  4,189,073 4,259,486 8,448,559  7,173,530 
 
DTaP=Diphtheria Tetanus and Acellular Pertussis Vaccine; MMR=Measles, Mumps, and Rubella Vaccine
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were set to receive the doses. The final value found in the table takes into account the 
coverage rate (Table 4.2). 
 
 
4.3 Descriptive Analysis of Reports 
 
There were 3245 AEFI reports submitted to the CAEFISS between 1997 -2008 (Table 
4.4) for the conditions of interest. The distribution of reports varied over the years with 
537 reports received in 1997 and only 214 reports received in 2006.  There seems to be 
no trend of a decline but on average remains steady between 200-300 reports per year. 
There were 282 reports related to anaphylaxis, 130 for GBS, 575 for HHE, 201 for 
thrombocytopenia, and 1794 for seizure related AEFI reports (Table 4.5).  The greatest 
number of reports came from nursing related health care professionals with 1454 reports; 
there were also a large proportion of reports that were from unknown reporters with 1268 
reports (Table 4.6).  
 
 
 4.4 Sensitivity of System 
 
 
4.4.1 Overall Senstivity  
 
The overall sensitivity for the various AEFI calculated varied greatly (Table 4.7). For 
influenza the sensitivity was found to be 93.6% and 136.3% for GBS and anaphylaxis 
respectively. For DTaP, sensitivity was found to be 15.0%, 1.0%, and 21.2% for 
anaphylaxis, HHE, and seizures respectively, and for MMR the rates were 16.5%, 52.7%, 
and 12.7% in relation to anaphylaxis, thrombocytopenia, and seizures respectively.  
Sensitivity trends over the years were also analyzed and looked at specifically for each 
AEFI and vaccine. 
 
 
4.4.2 Influenza 
 
Anaphylaxis related to influenza immunization fluctuated greatly between the years of 
1997 and 2008 (Figure 4.2).   The lowest rate was found in 2008 with 40.0% and was 
found to be as high as 322.2% in 2004. Based on the figure it was obvious that there were 
no general trends but rather a fluctuation in the yearly sensitivity related to anaphylaxis. 
In analysis of GBS it was found to have a maximum sensitivity of 187.5% in 2003 and as 
low as 20.0% in 1998.Both AEFI exhibited fluctuation year to year.  
Table 4.4 Descriptive Statistics of Selected Reports from 1997-2008 
 
4.4.3 DTaP 
 
Anaphylaxis related to DTaP immunization fluctuated greatly between the years of 1997 
and 2008. The highest rate was found in 2008 with 38.5% and was found to be as low as 
0% in multiple years (1998, 2002, and 2003). In analysis of HHE it was
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Table 4.4 Descriptive Statistics of Selected Reports from 1997-2008 
 
Year  Total Number of Reports Filed
Number of Selected 
Reports (N (%)) 
Total 46,407 3245 
1997  4,806 537 (11.2) 
1998  3,022 266 (8.8) 
1999  2,956 208 (7.0) 
2000  5,440 245 (4.5) 
2001  5,297 239 (4.5) 
2002  3,886 221 (5.7) 
2003  3,302 220 (6.7) 
2004 3,625 308 (8.5) 
2005  5,831 273 (4.7) 
2006  4,387 214 (4.9) 
2007  3,855 286 (7.4) 
 2008 * NA 228 (NA) 
 
Notes: *Selected reports met criteria for selection based on AEFI filing. Total values not 
available for 2008. 
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Table 4.5 Number of Reports Received by CAEFISS between 1997-2008 Related to 
Selected Adverse Events by AEFI 
 
AEFI Number of Reports (N) 
Anaphylaxis 282 
GBS 130 
HHE 575 
Thrombocytopenia 201 
Seizures 1794 
Convulsions 762 
Syncope 303 
Fever 1055 
 
 
Table 4.6 Number of Reports Received by CAEFISS between 1997-2008 Related to 
Selected Adverse Events by Reporters’ Affiliation 
 
Reporter’s Affiliation Number of Reports (N) 
Nursing 1454 
Physician 195 
Pharmacist 7 
IMPACT 129 
Manufacturer 171 
Other 19 
Consumer 1 
Unknown 1268 
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Table 4.7 Total and Yearly Sensitivity by Vaccine and AEFI for 1997-2008 
 
 
Influenza DTaP 
 GBS Anaphylaxis Anaphylaxis  HHE Seizures 
Year  E O Sens E O Sens E O Sens  E O Sens E O Sens 
Overall  91 85 93.6% 91 124 136.3% 154 23 15.0%  35,778 350 1.0% 3,936 835 21.2%
1997*  4 2 50.0% 4 5 125.0% 13 1 7.7%  3,097 175 5.7% 341 45 13.2%
1998  5 1 20.0% 5 5 100.0% 13 0 0.0%  3,033 38 1.3% 334 71 21.3%
1999  6 6 100.0% 6 6 100.0% 13 1 7.7%  3,002 24 0.8% 330 49 14.8%
2000  7 6 85.7% 7 13 185.7% 13 1 7.7%  2,961 33 1.1% 326 51 15.7%
2001  7 6 85.7% 7 13 185.7% 13 2 15.4%  2,916 38 1.3% 321 55 17.1%
2002  7 12 171.4% 7 14 200.0% 12 0 0.0%  2,886 37 1.3% 317 39 12.3%
2003  8 15 187.5% 8 5 62.5% 12 0 0.0%  2,858 33 1.2% 314 47 15.0%
2004  9 13 144.4% 9 29 322.2% 13 4 30.8%  2,928 36 1.2% 322 83 25.8%
2005  9 4 44.4% 9 10 111.1% 13 4 30.8%  2,941 36 1.2% 324 74 22.9%
2006  10 6 60.0% 10 5 50.0% 13 2 15.4%  3,002 18 0.6% 330 52 15.7%
2007  10 6 60.0% 10 15 150.0% 13 4 30.8%  3,049 35 1.1% 335 64 19.1%
2008  10 8 80.0% 10 4 40.0% 13 5 38.5%  3,104 22 0.7% 341 49 14.4%
Mean  90.8% 136.0% 15.4%  1.5% 17.6%
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Table 4.7 Continued 
  MMR 
 Anaphylaxis  Thrombocytopenia  Seizures 
Year  E O Sens  E O Sens  E O Sens 
Overall  103 17 16.5%  239 126 52.7%  7,174 910 12.7% 
1997*  9 2 22.2%  22 10 45.5%  653 127 19.4% 
1998  9 0 0.0%  21 7 33.3%  630 106 16.8% 
1999  9 0 0.0%  20 16 80.0%  604 74 12.3% 
2000  9 0 0.0%  20 16 80.0%  591 63 10.7% 
2001  9 1 11.1%  20 10 50.0%  591 58 9.8% 
2002  8 0 0.0%  19 8 42.1%  581 44 7.6% 
2003  8 1 12.5%  19 5 26.3%  570 47 8.2% 
2004  8 3 37.5%  19 10 52.6%  571 62 10.9% 
2005  8 1 12.5%  19 11 57.9%  582 72 12.4% 
2006  8 1 12.5%  20 11 55.0%  590 70 11.9% 
2007  9 4 44.4%  20 17 85.0%  598 85 14.2% 
2008  9 4 44.4%  20 6 30.0%  611 71 11.6% 
Mean  16.4%  53.1%  12.1% 
 
E=Expected; O=Observed; Sens=Sensitivity; DTaP=Diphtheria Tetanus and Acellular Pertussis Vaccine; MMR=Measles, 
Mumps, and Rubella Vaccine; HHE=Hypotonic-Hyporesponsive Episode; GBS=Guillan-Barre Syndrome 
 
Note: For DTaP Values for the year of 1997 were not included in the overall and the mean values due to the change from the 
whole cellular to acellular pertussis in that year.  
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Figure 4.2 Sensitivity for Anaphylaxis and GBS Related to Influenza Immunizations 
 
 
found to have a maximum sensitivity of 5.7% in 1997 and as low as 0.6% in 2006. There 
was a stable level of reporting across time with little fluctuation of the sensitivity value. 
Seizures had the highest sensitivity in 2004 with 25.8% and the lowest in 2002 with 
12.3% (Figure 4.3). 
 
 
4.4.4 MMR 
 
Anaphylaxis related to MMR immunization fluctuated greatly between the years of 1997 
and 2008 (Figure 4.4). The highest rate was found in 2008 with 44.4% and was found to 
be as low as 0% in several years (1998-2000). In analysis of Thrombocytopenia it was 
found to have a maximum sensitivity of 85% in 2007 and as low as 26.3% in 2003. 
Seizures had the highest sensitivity in 1997 with 19.4% and the lowest in 2002 with 
7.6%. 
 
 
4.5 Sensitivity Analysis 
 
A sensitivity analysis was conducted to assess the level of variation in the total sensitivity 
of the system based on the variation in the expected event rate (+/- 5%) and total number 
of administered doses (+/- 5%). A two-way analysis was also conducted using both 
variations of the doses and +/-5% of the event rate to create four different permutations.  
The difference from the primary model and the sensitivity analysis value was reported. 
For DTaP anaphylaxis ranged from 10.5% to 11.6%, HHE ranged from 0.6% to 0.7%, 
and seizures ranged from 8.9% to 10.3%.  
GBS 
Anaphylaxis 
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Figure 4.3 Sensitivity for anaphylaxis, HHE, and Seizures Related to DTaP 
Immunizations 
 
 
 
 
 
Figure 4.4 Sensitivity for Anaphylaxis, Thrombocytopenia, and Seizures Related to 
MMR Immunizations 
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For MMR, anaphylaxis ranged 12.0% to 14.0%. There was a greater total fluctuation 
with the rarer AEFI such as anaphylaxis, GBS, and thrombocytopenia (Table 4.8).  
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Table 4.8 One- and Two-way Sensitivity Analysis 
Influenza DTaP 
Anaphylaxis GBS Anaphylaxis  HHE Seizures 
Model Used Sens Δ Sens Δ Sens Δ  Sens Δ Sens Δ 
Primary 136.3% 93.6% 15.0%   1.0% 21.2% 
 
One-way  
Expected Rate  
"- 5%" 144.2% 7.9% 98.8% 5.2% 15.8% 0.8%  1.0% 0.1% 22.4% 1.2% 
"+5%" 130.5% -5.7% 89.5% -4.2% 14.3% -0.7%  0.9% 0.0% 20.2% -1.0%
Administered Doses  
"- 5%" 144.2% 7.9% 98.8% 5.2% 15.8% 0.8%  1.0% 0.1% 22.4% 1.2% 
"+5%" 130.5% -5.7% 89.5% -4.2% 14.3% -0.7%  0.9% 0.0% 20.2% -1.0%
 
Two-way  
Expected 
Rate 
Administered 
Doses            
"-5%" "-5%" 151.2% 15.0% 103.7% 10.0% 16.5% 1.6%  1.1% 0.1% 23.5% 2.3% 
"-5%" "+5%" 136.3% 0.0% 93.4% -0.2% 15.0% 0.1%  1.0% 0.0% 21.3% 0.1% 
"+5%" "+5%" 124.0% -12.3% 85.0% -8.6% 13.5% -1.4%  0.9% -0.1% 19.2% -2.0%
"+5%" "-5%" 136.3% 0.0% 93.4% -0.2% 15.0% 0.1%  1.0% 0.0% 21.3% 0.1% 
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Table 4.8 Continued 
MMR 
Anaphylaxis  Thrombocytopenia  Seizures 
Model Used Sens Δ  Sens Δ  Sens Δ 
Primary  16.5%  52.7%  12.7% 
  
One-way   
Expected Rate   
"- 5%" 17.3% 0.9%  55.5% 2.8%  13.4% 0.7% 
"+5%" 15.7% -0.7%  50.2% -2.5%  12.1% -0.6%
Administered Doses   
"- 5%" 17.3% 0.9%  55.5% 2.8%  13.4% 0.7% 
"+5%" 15.7% -0.7%  50.2% -2.5%  12.1% -0.6%
  
Two-way   
Expected 
Rate 
Administered 
Doses         
"-5%" "-5%" 18.3% 1.8%  58.3% 5.6%  14.1% 1.4% 
"-5%" "+5%" 16.5% 0.0%  52.7% 0.0%  12.7% 0.0% 
"+5%" "+5%" 14.9% -1.5%  47.7% -5.0%  11.5% -1.2%
"+5%" "-5%" 16.5% 0.0%  52.7% 0.0%  12.7% 0.0% 
 
Sens=Sensitivity, Δ=Difference between Primary model and sensitivity analysis value; DTaP=Diphtheria Tetanus and 
Acellular Pertussis Vaccine; MMR=Measles, Mumps, and Rubella Vaccine; HHE=Hypotonic-Hyporesponsive Episode; 
GBS=Guillan-Barre Syndrome 
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CHAPTER 5. DISCUSSION 
 
 
5.1 Overview of Findings 
 
This is the first study to assess the sensitivity of the CAEFISS. Sensitivity varied by 
vaccines and within vaccines specific AEFI, from 1997 to 2008.  The overall sensitivity 
varied by selected AEFI from 1.0% to 136.3%. The greatest variations were found in 
anaphylaxis which was analyzed in all three of the vaccines examined. Variations in 
sensitivity were found between vaccines, AEFI within the same vaccine and over within 
and among vaccines. There was evidence that age group, timing of event, and rarity also 
affected sensitivity within vaccines.  
 
 
5.1.1 Comparison to Past Literature 
 
As discussed in Chapter 2, the only major study to look at the assessment of sensitivity of 
a vaccine AEFI surveillance system was that of Rosenthal et al. (1995). This study had 
four similar AEFI that overlapped with those in the paper by Rosenthal et al. (1995): 
seizures associated with DTaP and MMR, HHE with DTaP, and thrombocytopenia with 
MMR.  
 
In comparing thrombocytopenia associated with MMR, the sensitivity was less than one 
percent in the study by Rosenthal et al. (1995) and 52.7% in the present study. This 
difference may be explained in large part by the introduction of the IMPACT program 
and its specific targeting of thrombocytopenia through the use of the active surveillance 
system (Jadavji, Scheifele, & Halperin 2003).  
 
Sensitivity for seizures related to DTaP was higher in the study by Rosenthal et al. (1995) 
than in the present study. Rosenthal et al. (1995) found sensitivity values of 24% versus 
17.6% in this study. While these differences are significant, note that a whole-cell 
pertussis vaccine known to be associated with a higher expected rate of seizures was used 
during the time period that Rosenthal analyzed. The vaccine used during the course of 
this study is acellular with a lower of incidence of seizure as discussed previously. This 
risk of seizures was of a greater concern to clinicians during that time period than during 
the period studied here, so it was more likely that clinicians would report its appearance. 
This has become less of a concern as a result of the formulation change, a downward 
trend of reporting by clinicians and the public was expected. The present study excluded 
any reports related to the whole-cell pertussis vaccines, and for the overall value 
calculation, all data from 1997 were excluded to ensure that this transition year did not 
affect the sensitivity.  
 
Sensitivity for seizures related to MMR was also higher in the study by Rosenthal et al. 
(1995) than in the present study. Rosenthal and his colleagues found sensitivity values of 
27% versus 12.1% in this current study. This may be related to the correlation between 
DTaP and MMR. As discussed above, the concern of clinicians at the time of the 
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Rosenthal study for seizures was much higher than recent years.MMR and DTaP 
administration are closely related and often administered at similar visits. There were a 
large proportion of reports of seizures in this study in which both DTaP and MMR were 
both reported to have been administered.  
 
This study also found lower sensitivity associated with HHE (approximately 4% versus 
1.0% in our study). This difference may be associated with a general downward trend in 
reporting. This was expected, because as a vaccine is used more often, clinicians become 
more acclimated to its use and associated AEFI leading to fewer reports.  
 
Although the results varied, Rosenthal and colleagues made similar conclusions with 
what specific factors affected sensitivity, such as clinical seriousness, temporal 
proximity, and healthcare awareness. These findings paralleled this study’s finding that 
sensitivity was affected by both temporal proximity and expected rates of occurrence.   
The differences of results may be due to variations in the systems and timing of the 
studies. The time period in which their analysis was conducted (1985-1990) differed from 
that in this study (1997-2008).  
 
 
5.1.2 Results by Vaccines 
 
5.1.2.1 AEFI Related to Influenza Vaccination 
 
In the present study, influenza vaccination was used as an indicator of all adult 
immunizations. Estimates of sensitivity for influenza vaccine–associated reporting of 
anaphylaxis and GBS were limited to those aged 12 years and older. The highest adult 
sensitivities were for GBS and anaphylaxis (136.3% and 93.6%, respectively). It was 
evident that the immunization of adults with influenza vaccine had the highest sensitivity 
in the study.  
 
Sensitivity of both GBS and anaphylaxis related to influenza vaccination were highly 
unstable when analyzed on a yearly basis. This variation may be due to the rarity of the 
events. This rarity led to a small number of expected events which made small variations 
in the actual data appear more significant than they truly were in the overall sensitivity. 
This could be even more pronounced when other factors within the population impact the 
occurrence of an AEFI. One example of this confounding is the occurrence of GBS due 
to an outbreak of Campylobacter.  
 
Other factors such as the rate of occurrence and the assumption that all cases are true 
cases could also impact these rare adverse events. Rare events have an increased 
likelihood of being misreported because reporters may be less experienced with a rare 
AEFI. This lack of experience may also increase the likelihood of misreporting and 
misdiagnosing adverse events, leading to inconsistency in reporting. This inconsistency is 
even more pronounced without case-definitions.  Without the assistance of case 
definitions the literature has shown clinicians’ case determinations are inconsistent (Kohl 
et al. 2008). Inconsistency in reporting may be one of the major causes of greater 
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variation in reporting, and this effect would be much more pronounced for adverse events 
with low rates of occurrence.  
 
5.1.2.2 AEFI Related to DTaP Vaccination 
 
Estimates of sensitivity for DTaP related AEFI were completed for anaphylaxis, HHE, 
and seizures. The overall sensitivity was found to be 15.0% for anaphylaxis, 1.0% for 
thrombocytopenia, and 21.2% for seizures.   
 
Seizures had the highest sensitivity of the three AEFI related to DTaP. The higher 
reporting of seizures maybe due to the past experience with the whole-cell pertussis 
vaccine, which was changed to the acellular formulation due to concerns with the rate of 
seizures related to vaccination. Although the rate of occurrence of the AEFI was 
decreased, this may still be an area of concern for clinicians. Seizures are also a relatively 
more common adverse event and displayed a steady sensitivity over time.   
 
HHE was the most common of the three AEFI and exhibited the lowest sensitivity. HHE 
was the most stable sensitivity of all the AEFI in the study and within DTaP related 
AEFI. This is most likely due to HHE having the highest rate of occurrence for DTaP 
AEFI and AEFI in the study as a whole. Sensitivity for HHE and seizures were stable 
over the years.  
 
Anaphylaxis related to DTaP vaccination was not the highest sensitivity within DTaP. 
This varies from the other two vaccines looked at in the study, in which anaphylaxis was 
the highest of the AEFI within vaccines. The results of anaphylaxis within DTaP did 
parallel those in the other vaccines in terms of year to year sensitivity, which was found 
to vary greatly.   
 
5.1.2.3 AEFI Related to MMR Vaccination 
 
Estimates of sensitivity for MMR related AEFI were completed for anaphylaxis, 
thrombocytopenia, and seizures. The overall sensitivity was found to be 16.5% for 
anaphylaxis, 52.7% for thrombocytopenia, and 12.7% for seizures.  
 
Thrombocytopenia was found to have the highest sensitivity of the three AEFI related to 
MMR. This may be explained by the IMPACT program and its specific targeting of 
thrombocytopenia through the use of the active surveillance system (Jadavji et al. 2003). 
It may be difficult to determine how much of this is due to the IMPACT program. Only 
33 out of the 239 thrombocytopenia reports were coded as IMPACT, some reports may 
be related to the program and labeled as reports from nurses or physicians. 
 
Seizures were the most common of the three AEFI and exhibited the lowest sensitivity. 
Sensitivity for seizures was stable over the years when compared to thrombocytopenia 
and anaphylaxis. This variation of anaphylaxis and thrombocytopenia may be due to the 
rarity of the events.  
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5.1.3 Adult versus Pediatric Reporting 
 
In the present study, influenza vaccination was used as an indicator of adult 
immunizations. DTaP and MMR were predominantly used as indicators of immunization 
in the pediatric population. Estimates of sensitivity for influenza vaccine–associated 
reporting of anaphylaxis and GBS were limited to those aged 12 years and older, whereas 
DTaP and MMR sensitivity were limited to preschool-aged populations to the age of 8 
years. The highest adult sensitivities were for GBS and anaphylaxis. There was evidence 
that the immunization of adults with influenza vaccine had a higher sensitivity. It is 
important to note that the AEFI selected for influenza were both rare and this may limit 
the ability to conclude that adult sensitivity was higher than that of the pediatric 
population.  
 
This differentiation of adult immunization and pediatric immunization may be attributed 
to factors pertaining to the individual responsible for reporting and administering the 
vaccines (Duclos, Hockin, Pless, & Lawlor 1997). Further research would be required to 
help better understand these findings.  
 
 
5.1.4 Common versus Rare Adverse Events 
 
The AEFI considered within this study varied in rate of occurrence with some being more 
common than others. As discussed in the Methods chapter, these vaccines were selected 
on the basis of the variation in their expected rates of occurrence in order to compare 
more common AEFI with rarer AEFI (Table 5.1).  The event with the highest expected 
rate of occurrence was HHE associated with DTaP. This adverse event was also 
associated with the lowest overall sensitivity rate in this study. Seizures with both MMR 
and DTaP had lower sensitivity of 12.7% and 21.2%, respectively. They were the 2nd and 
3rd lowest sensitivity values found. In contrast, the three most common adverse events 
were among the lowest sensitivity values of the study and exhibited the greatest stability 
from year to year.  
 
AEFI that have higher rates of occurrence appear to have a lower sensitivity and more 
stable sensitivity over time. As an AEFI becomes more common, it will be more 
frequently seen by those administering the vaccine, and its sensitivity may decrease and 
the stability of reporting may increase. Rarer events have a greater likelihood that they 
will be misdiagnosed than more common events. This misdiagnosis may be due to a lack 
of familiarity with the event because of its rarity.  
 
As discussed above, inconsistencies in reporting may also affect the stability of 
sensitivity over time and are more pronounced in rare adverse events. Rare AEFI may 
also be more greatly affected by smaller variations in their actual occurrence.  A greater 
number of reports would be needed to vary the sensitivity of a common AEFI with a 
higher rate of occurrence. Rarer adverse events had the greatest variations when estimates 
were changed in the model. 
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Table 5.1 Ordered Expected Occurrence per Million Doses from Lowest to Highest 
 
Order Adverse Event (Vaccine) 
Rate of 
Occurrence 
per Million 
Doses 
Overall 
Sensitivity 
Average 
Sensitivity 
Sensitivity 
Range 
1 HHE (DTaP) 14000 1.0% 1.5% 0.6%-1.3% 
2 Seizures (MMR) 1000 12.7% 12.1% 7.6%-19.4% 
3 Seizures (DTaP) 220 21.2% 17.6% 12.3%-25.8% 
4 Thrombocytopenia  (MMR) 33 52.7% 53.1% 
26.3%-
85.0% 
5 Anaphylaxis (MMR) 14 16.5% 16.4% 
0.0%-
44.4% 
6 Anaphylaxis (DTaP) 9 15.0% 15.4% 
0.0%-
38,5% 
7 Anaphylaxis (Influenza) 1 93.6% 136.0% 
40.0%-
322.2% 
8 GBS (Influenza) 1 136.3% 90.8% 20.0%-187.5% 
 
 
5.1.5 Timing of AEFI Onset 
 
For all three of the vaccines analyzed, the most acute AEFI assessed was anaphylaxis, a 
serious systemic reaction that sometimes occurs in response to any vaccine and 
commonly occurs within minutes to hours after administration (Coop et al. 2008; 
Erlewyn-Lajeunesse, Bonhoeffer, Ruggeberg, & Heath 2007; Kagy & Blaiss 1998). 
Anaphylaxis related to influenza vaccination was found to have the highest sensitivity in 
the study, with an overall sensitivity of 136.6%. This value was the only value in the 
study that was found to be above 100%, meaning that there was more reporting than 
expected. This high sensitivity may, in part, be due to over-reporting or a misdiagnosis of 
the adverse event.  
 
AEFI with slower onsets of days to weeks had lower sensitivities. GBS related to 
influenza vaccination, seizures related to MMR vaccination, and HHE related to DTaP 
were the selected to represent AEFI that have a longer duration of onset post 
immunizations. These AEFI were also the lowest sensitivities in their respective 
vaccines. This may show that when an AEFI is temporally separated from the 
administration of the vaccine, it is less likely to be reported. This may be due to the more 
difficult task of finding correlation to the vaccine days or weeks after its administration, 
as compared to minutes and hours after its administration.   
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In addition to being temporally acute, anaphylaxis is also a rare AEFI as discussed 
previously. Examination of trends over years for all three vaccines showed that 
anaphylaxis was present with the greatest variations over time. Thus, not only does the 
temporal acuity of an adverse event seem to increase the reporting, but it also may be a 
factor in determining the instability of reporting over time. This may also be clouded by 
the general rarity of anaphylaxis.  
 
 
5.1.6 Sensitivity Analysis 
 
A sensitivity analysis of this study was conducted to assess the level of variation in the 
overall sensitivity. One-way and two-way analyses were conducted for the two major 
values in the model: the expected rate and the number of administered doses. The greatest 
variation was seen with the rare adverse events. GBS and anaphylaxis related to influenza 
vaccination had a variation of 10.0% and 15.0%, respectively. The most common adverse 
events such as HHE and seizures related to DTaP had variations of 0.1% and 2.3%, 
respectively. This can be attributed to the fact that a single additional case can cause great 
variation in the calculated sensitivity of rare adverse events, compared to the more 
common adverse events. The results from the sensitivity analysis can be used to better 
determine how much credence to lend to these results. It can be assumed that the specific 
findings of the more common adverse events are more robust. In contrast, those rare 
adverse events need greater scrutiny and more complex analysis when large changes in 
sensitivity occur. This adds increased importance for the need to standardize reporting 
through standard case definitions, in order to stabilize the sensitivity. Therefore when 
large variations in reports occur, there can be a quicker response to the number of reports, 
rather than a need for further assessment into the PPV of the reports. Reporters will be 
diligent in reporting cases that meet a level of diagnostic certainty as comfort with case-
definitions increases. 
 
 
5.2 Limitations 
 
 
5.2.1 Expected Rates of AEFI 
 
Expected rates had to be estimated based on previous clinical trials and epidemiological 
studies, which may not produce perfect expected rates. In order to address this study 
limitation, a thorough systematic search was conducted using multiple sources. In 
situations where multiple values were found, the best designed studies were used as the 
primary value. Additionally, to ensure that values were robust, a sensitivity analysis of 
this study was utilized to assess how greatly the variation in the expected rates would 
affect the results. The variation in the expected rate affected the rarer adverse events to a 
great degree, as discussed previously. The greatest fluctuation was seen in anaphylaxis 
associated with influenza vaccination. It varied from 124.0% to 151.2%. In more 
common adverse events such as HHE, the variation due to these estimates was far less 
pronounced, varying by only 0.1%.  
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5.2.2 Coverage Rates 
 
Coverage rates were used in the model to compute the expected number of administered 
doses. As discussed in past chapters, these values as discussed in past chapters were 
drawn from survey data.  In some of the cases of DTaP, MMR, and influenza the surveys 
were not conducted yearly. In years where there were no surveys completed, an 
extrapolation of the past and future coverage rates was used, assuming a linear growth. 
This assumption may not be valid as there may be unknown but important factors 
affecting the coverage rate. This may not be as distinct in DTaP and MMR vaccinations 
since their rates for all the doses held within 1-2% of each other throughout the time 
period. The greatest impact this may have is in the influenza vaccination which had a 
great increase in rate over the time period analyzed. To ensure that our estimations were 
not unrealistic a double check was conducted using the number of influenza doses 
distributed nationally. Dose distribution data were provided by PHAC who received the 
data from the manufacturers.  It was found that estimates for doses administered were 
reasonably close to these values (Table 5.2). The estimates never exceeded the number of 
doses distributed. To also insure that estimates did not highly impact the final values as a 
part of the sensitivity analysis conducted all coverage rates were adjusted by +/-5% for 
both the one-way analysis and two-way analysis. It was found that this adjustment had 
the greatest impact on the rarer adverse events similar to the results found with the 
expected rates. 
  
 
Table 5.2 Comparison of Estimated Influenza Vaccine Doses Administered to Reported 
Doses Distributed 
Year Estimated Doses 
Administered 
Doses Distributed 
Overall 90,779,438 115,824,359 
1997 3,771,992 5,249,999 
1998 4,831,281 5,062,361 
1999 5,913,757 5,750,237 
2000 7,025,995 12,199,380 
2001 7,125,779 9,330,555 
2002 7,365,887 10,477,216 
2003 7,599,565 11,080,935 
2004 8,524,581 11,309,614 
2005 9,468,100 11,494,459 
2006 9,589,726 11,893,503 
2007 9,715,953 11,443,640 
2008 9,846,822 10,532,460 
 
Note: These numbers are for total doses of all types of influenza vaccine marketed in 
Canada 
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5.2.3 Issues with Spontaneous Systems 
 
One Typical key limitation in the use of spontaneous reporting system data is missing and 
incomplete reports. This inconsistency in data makes it difficult to analyze many of the 
reports since they may not contain all the necessary data. This limitation does not impact 
our study, because the information was limited to age of patient, year of report, vaccines 
administered, and type of adverse event which are almost always present within a report.  
 
Another limitation with reports associated with spontaneous systems is the PPV of the 
reports and how this may affect the sensitivity. Two factors can affect whether a report 
represents a true adverse event causally related to the vaccine. The first factor is that of 
the factuality of the report. In other words, is the report of a specific AEFI truly related to 
that AEFI, or is it a misdiagnosis? For anaphylaxis this is especially problematic since 
rapid institution of treatment can alter an evolving event and make it impossible to 
determine, after the fact, whether it in fact meets the definition of anaphylaxis. This issue 
can be less problematic for other AEFI such as thrombocytopenia. The second issue 
relates to causality. Not all reports received represent causally associated adverse events 
because temporal association does not prove casual association. For example, background 
disease occurrence in the population may have caused an event to occur but still may be 
reported as an AEFI. This may be evident with such AEFI as GBS and 
thrombocytopenia. Both of these issues may lead to excess reporting and be the cause of 
higher than expected sensitivity and maybe much more pronounced in rare AEFI. In past 
studies of vaccine adverse event reporting systems, some of the reports were eliminated 
based on timing of the adverse events in correlation with vaccination. In this study no 
reports were eliminated because of the belief that that inclusion of those reports is helpful 
in assessing the extent of reporting.  
 
 
5.3 Implications 
 
This study is the first of its kind for the Canadian system. Further research and utilization 
of the data are necessary. Despite the inherent limitations of spontaneous systems, it is 
important to strive for a highly standardized system with regular measurement of 
characteristics like sensitivity to understand to what degree variation exists. A continuous 
and annual evaluation of the quality of the system is important for the purpose of 
improvement and may help strengthen public confidence. Spontaneous systems are not 
rigid in nature but rather are fluid entities, so annual assessment would be essential to any 
successful system. Current guidelines recommend annual assessment of sensitivity and 
other characteristics in order to make proper adjustments to the system that may result in 
increased and higher quality reporting (German 2001). Sensitivity as an assessment tool 
of the system holds special importance since the model to create it takes into account 
changes in population, coverage, and administration. This value is more useful in 
assessing the system than simply looking at the number of reports annually. VAERS 
currently conducts this type of assessment annually as a retrospective assessment of the 
system.  
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The systems are dependent on outside reporters, so perception of those outside the system 
is relevant (Wysowski & Swartz 2005). A better understanding of the system will not 
only raise further research questions but also will serve as a tool for hypothesis 
generation and quality improvement initiatives. To improve public confidence 
publication of these results and other results utilizing the reports must be published. This 
will improve public confidence for a few reasons. 1) The results will make evident to the 
public that their reports are being utilized. 2) The publication of these results will 
increase public confidence that the system receives a substantial number of reports, even 
for rare adverse events, at a level that is high enough to maintain the systems primary 
goal. 3) The system exhibits ability for response to increased reports. 4) Further efforts to 
improve the system are continually being made. 5) Future research will continue to better 
understand reporting and possibly look at greater applications and assessment of the 
reports. 
 
The results show that although the overall sensitivity for each AEFI was quite variable, 
the system had sensitivities that were as high as seen in past research. Year by year 
analysis showed steady rates in more common adverse events and greater variation in 
more rare events. This variation over time gives greater evidence for the need of 
implementation of standardized case-definitions to be used in reporting. Further 
education of those administering vaccines coupled with incorporation of the case 
definitions into the reporting forms may prove to be beneficial in assisting to stabilize the 
fluctuation of sensitivity. This was especially apparent in the reporting of anaphylaxis, 
which is commonly misdiagnosed and misreported. Implementation of such case-
definitions may prove to improve specificity and PPV, and help limit variation of 
sensitivity overtime. 
 
Implementation of case-definitions has been at the forefront of current international 
vaccine safety initiatives. The Brighton Collaboration is an international collaboration 
aiming to help evaluate issues related to vaccine safety. One of the major goals of the 
collaboration was to standardize case definitions that can be used internationally. 
Standardization of these case definitions would help comparability of research and help 
in monitoring reporting (Ball et al. 2002; Bonhoeffer et al. 2002; Kohl et al. 2007). The 
case-definitions as well as published studies utilizing the case-definitions are accessible 
online to the public. However, integration of these case definitions into the reporting 
forms is only now beginning.   
 
There are published papers discussing the Brighton collaboration. The majority of the 
published papers has been on the discussion of the creation and need for case definitions. 
The case-definitions may help in data comparability in clinical trials, surveillance 
systems, and retrospective epidemiological studies (Clark & Camargo 2007). It is 
important to note that the case-definitions are not meant to be used for the identification 
of a causal assessment or establishing possible management for the adverse event.  
Rather, they are meant to help define various levels of diagnostic certainty based on the 
current literature using specified criteria unique to the adverse event. The case definitions 
are placed at three different levels of evidence with different diagnostic criteria being 
 41 
 
placed in one of the three levels. These levels are used to then assess the likelihood of a 
causal association.  
 
Research is also ongoing on the use and applications of these case-definitions. One 
published paper looked at assessing the applicability, reliability, sensitivity and 
specificity of applying the case definitions to the VAERS data (Kohl et al. 2008). The 
study used the case definitions for fever, generalized convulsive seizures, HHE, 
intussusceptions, nodule at injection site, and persistent crying.  The study concluded that 
the use of the case definitions had high sensitivity and specificity when compared to 
clinician review of the case reports. The study confirms the importance of these case-
definitions and the need for continued development and acceptance in vaccine safety 
surveillance systems globally. Currently, the CAEFISS has begun plans and various 
projects on the implementation and utilization of these case-definitions in relation to 
anaphylaxis. The findings of this study strengthen the importance of this initiative. 
 
 
5.4 Future Research 
 
 
5.4.1 PPV Analysis 
 
Although this is an assessment of surveillance systems, this study, along with previous 
research, suggests further value and benefit in the assessment of the PPV of a system as 
well (German 2000). Assessment of the PPV analysis will enable the researchers to better 
understand the quality and the types of reports being received. In this assessment of 
sensitivity, it is assumed that the PPV is 100%, in other words, all reports received are 
true reports as well as casually associated. In reality, this may not hold true and many 
reports may be erroneous and need to be assessed on a report by report basis. A high PPV 
refers to a system in which a large proportion of reports received are true positives, 
versus a low PPV which is evidence of a system receiving many false positive reports. A 
low PPV may be a sign of wasted resources and the need for the implementation of 
education and stricter case-definitions for reporters.  
 
Currently, Canada is in the pilot phase of applying many of these case-definitions to its 
systems. Applications of these case-definitions and studies on how they affect both the 
sensitivity and the PPV would be of importance. As evidenced by the results in this 
study, especially with anaphylaxis, there may be over-reporting. The implementation of 
case-definitions and education concerning these adverse events may help stabilize the 
variation in reporting many of the adverse events. 
 
5.4.2 Policy and Reporter Assessment 
 
The impact that other factors may have on the sensitivity of the reporting system is also 
of interest. In our current study, we assessed the specific characteristics of the AEFI 
itself, such as vaccine, rate of occurrence, age of patient, and timing of adverse event. 
Reporting may also be impacted by factors associated with the reporters, such as 
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professional affiliation. The impact of professional affiliation on reporting is tied closely 
with the type of policy in various provinces. In some provinces the majority of 
vaccination is completed by public health officials rather than nurses and physicians in 
practice settings. Policy impacts the mandates around reporting.  The policies of some 
provinces make adverse event reporting mandatory, while it is voluntary in others. It is 
unknown whether these policy variations impact the reporting system and how they 
would impact the sensitivity of the system.  
 
 
5.4.3 Trending Analysis Using Moving Averages 
 
The results of this study showed evidence of variation in the year by year analysis. It was 
difficult to ascertain which factors and which years were of importance; this was 
especially true in rarer AEFI. The methodology of moving averages has been used in 
business and disease outbreak research. A moving average is a form of average which has 
been adjusted to allow for seasonal or cyclical components of a time series. Moving 
average smoothing is a smoothing technique used to make the long term trends of a time 
series clearer.  
 
The application of the moving average for vaccine safety has not been reported in the 
literature. Small studies have attempted to apply the methodology to adverse event 
reporting within hospitals (Morton 2009). The application of such a methodology would 
allow for assessment of trending as well as a potential for signaling that maybe more 
apparent. The application of this methodology to adverse event reporting is still in its 
infancy and has not been applied to sensitivity. In application to a rare event such as GBS 
related to influenza vaccinations (Figure 5.1), we see that this methodology limits the 
variation and depicts a smoother curve.  
 
 
5.5 Conclusion 
 
This is the first assessment of the sensitivity of the CAEFISS, and this study found that 
the system has reasonable ability to detect AEFI on a national level. This study found that 
the overall sensitivity of the CAEFISS varied from 1.0% to 136.6% for various adverse 
events for the years 1997-2008. CAEFISS had comparable sensitivity to previously 
completed studies. Many of the AEFI had sensitivity values higher than the 5%-10% 
range traditionally seen in other passive surveillance systems related to adverse events 
(Begaud, Martin, Haramburu, & Moore 2002). The greatest variation of sensitivity was 
seen between vaccines. Rarity and timing of the AEFI also appeared to have an impact on 
the sensitivity. Variation of sensitivity and the variation found in the sensitivity analysis 
lend credence to the further development and implementations of case definitions for 
rarer adverse events, especially anaphylaxis. This type of analysis should be conducted 
annually for continued assessment of the system. Further research of other factors that 
impact reporting is necessary.  
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Figure 5.1 Application of Moving Averages to GBS Related to Influenza Vaccination; 1-, 
3-, and 5- Year Moving Averages 
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